Avrobio Inc (AVRO)

1.48 +0.04 (+2.78%) USD  |  NASDAQ  |  May 31, 16:00
1.48 0.00 (0.00%) After-Hours: 20:00
More

Avrobio Cash from Financing (Quarterly): 0.03M for March 31, 2024

Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Upgrade now.
Date Value
March 31, 2024 0.03M
December 31, 2023 0.059M
September 30, 2023 0.178M
June 30, 2023 -16.32M
March 31, 2023 0.055M
December 31, 2022 0.059M
September 30, 2022 0.06M
June 30, 2022 0.001M
March 31, 2022 0.142M
December 31, 2021 14.94M
September 30, 2021 0.022M
June 30, 2021 14.60M
March 31, 2021 0.799M
December 31, 2020 70.70M
September 30, 2020 0.06M
Date Value
June 30, 2020 8.191M
March 31, 2020 93.66M
December 31, 2019 0.03M
September 30, 2019 129.47M
June 30, 2019 0.238M
March 31, 2019 0.252M
December 31, 2018 -0.139M
September 30, 2018 -3.255M
June 30, 2018 105.47M
March 31, 2018 58.21M
December 31, 2017 13.97M
September 30, 2017 -0.032M
June 30, 2017 -0.051M
March 31, 2017 3.487M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

-16.32M
Minimum
Jun 2023
129.47M
Maximum
Sep 2019
15.85M
Average
0.101M
Median

Cash from Financing (Quarterly) Benchmarks

AIM ImmunoTech Inc 2.829M
Perspective Therapeutics Inc 166.33M
Protalix BioTherapeutics Inc 0.00
Electromed Inc 0.056M
Armata Pharmaceuticals Inc 34.93M

Cash from Financing (Quarterly) Related Metrics

Cash from Operations (Quarterly) -7.569M
Free Cash Flow -50.48M
Free Cash Flow Per Share (Quarterly) -0.169
Free Cash Flow Yield -76.39%